<PubmedArticle>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">20091020</PMID>
<DateCompleted>
<Year>2010</Year>
<Month>10</Month>
<Day>22</Day>
</DateCompleted>
<DateRevised>
<Year>2018</Year>
<Month>11</Month>
<Day>13</Day>
</DateRevised>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1432-0428</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>53</Volume>
<Issue>3</Issue>
<PubDate>
<Year>2010</Year>
<Month>Mar</Month>
</PubDate>
</JournalIssue>
<Title>Diabetologia</Title>
<ISOAbbreviation>Diabetologia</ISOAbbreviation>
</Journal>
<ArticleTitle>Predictive power of screening for antibodies against insulinoma-associated protein 2 beta (IA-2beta) and zinc transporter-8 to select first-degree relatives of type 1 diabetic patients with risk of rapid progression to clinical onset of the disease: implications for prevention trials.</ArticleTitle>
<Pagination>
<MedlinePgn>517-24</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1007/s00125-009-1618-y</ELocationID>
<Abstract>
<AbstractText Label="AIMS/HYPOTHESIS" NlmCategory="OBJECTIVE">We investigated whether screening for insulinoma-associated protein (IA-2) beta (IA-2beta) autoantibodies (IA-2betaA) and zinc transporter-8 (ZnT8) autoantibodies (ZnT8A) improves identification of first-degree relatives of type 1 diabetic patients with a high 5-year disease risk, which to date has been based on assays for insulin autoantibodies (IAA), GAD autoantibodies (GADA) and IA-2 autoantibodies (IA-2A).</AbstractText>
<AbstractText Label="METHODS" NlmCategory="METHODS">IA-2betaA and ZnT8A (using a ZnT8 carboxy-terminal hybrid construct, CW-CR, carrying 325Arg and 325Trp) were determined by radiobinding assay in 409 IAA(+), GADA(+) and/or IA-2A(+) siblings or offspring (&lt;40 years) of type 1 diabetic patients consecutively recruited by the Belgian Diabetes Registry. The median (interquartile range) age of the first-degree relatives was 12 (6-19) years.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">Of the first-degree relatives, 24% were IA-2A(+) (n = 97), 14% (n = 59) IA-2betaA(+) and 20% (n = 80) ZnT8A(+). IA-2betaA and ZnT8A were significantly (p &lt; 0.001) associated with IA-2A and prediabetes (n = 86); in IA-2A(-) first-degree relatives (n = 312) the presence of IA-2betaA and ZnT8A was associated with an increased progression rate to diabetes (p &lt; 0.001). Positivity for IA-2A and/or ZnT8A emerged as the most sensitive combination of two markers to identify first-degree relatives with a 5-year progression rate to diabetes of 45% (survival analysis) and as strongest predictor of diabetes (Cox regression analysis). Omission of first-degree relatives protected by HLA-DQ genotypes or maternal diabetes reduced the group to be followed from n = 409 to n = 246 (40%) with minor loss in the number of prediabetic IA-2A(+) or ZnT8A(+) first-degree relatives identified (n = 3).</AbstractText>
<AbstractText Label="CONCLUSIONS/INTERPRETATION" NlmCategory="CONCLUSIONS">IA-2A(+) and/or ZnT8A(+) first-degree relatives may be the participants of choice in future secondary prevention trials with immunointervention in relatives of type 1 diabetic patients.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>De Grijse</LastName>
<ForeName>J</ForeName>
<Initials>J</Initials>
<AffiliationInfo>
<Affiliation>Diabetes Research Center, Brussels Free University-VUB, Laarbeeklaan 103, B-1090 Brussels, Belgium.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Asanghanwa</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Nouthe</LastName>
<ForeName>B</ForeName>
<Initials>B</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Albrecher</LastName>
<ForeName>N</ForeName>
<Initials>N</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Goubert</LastName>
<ForeName>P</ForeName>
<Initials>P</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Vermeulen</LastName>
<ForeName>I</ForeName>
<Initials>I</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Van Der Meeren</LastName>
<ForeName>S</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Decochez</LastName>
<ForeName>K</ForeName>
<Initials>K</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Weets</LastName>
<ForeName>I</ForeName>
<Initials>I</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Keymeulen</LastName>
<ForeName>B</ForeName>
<Initials>B</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Lampasona</LastName>
<ForeName>V</ForeName>
<Initials>V</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Wenzlau</LastName>
<ForeName>J</ForeName>
<Initials>J</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Hutton</LastName>
<ForeName>J C</ForeName>
<Initials>JC</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Pipeleers</LastName>
<ForeName>D</ForeName>
<Initials>D</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Gorus</LastName>
<ForeName>F K</ForeName>
<Initials>FK</Initials>
</Author>
<Author ValidYN="Y">
<CollectiveName>Belgian Diabetes Registry</CollectiveName>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2009</Year>
<Month>11</Month>
<Day>29</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>Germany</Country>
<MedlineTA>Diabetologia</MedlineTA>
<NlmUniqueID>0006777</NlmUniqueID>
<ISSNLinking>0012-186X</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D001323">Autoantibodies</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D027682">Cation Transport Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D006683">HLA-DQ Antigens</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D007328">Insulin</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C486299">SLC30A2 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.1.3.48</RegistryNumber>
<NameOfSubstance UI="D054635">Receptor-Like Protein Tyrosine Phosphatases, Class 8</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>J41CSQ7QDS</RegistryNumber>
<NameOfSubstance UI="D015032">Zinc</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000293">Adolescent</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001323">Autoantibodies</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000737">chemistry</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D027682">Cation Transport Proteins</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000096">biosynthesis</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002648">Child</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D003922">Diabetes Mellitus, Type 1</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005192">Family Health</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006683">HLA-DQ Antigens</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007328">Insulin</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011237">Predictive Value of Tests</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D054635">Receptor-Like Protein Tyrosine Phosphatases, Class 8</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000096">biosynthesis</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015032">Zinc</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000737">chemistry</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData>
<History>
<PubMedPubDate PubStatus="received">
<Year>2009</Year>
<Month>06</Month>
<Day>08</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted">
<Year>2009</Year>
<Month>11</Month>
<Day>05</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez">
<Year>2010</Year>
<Month>1</Month>
<Day>22</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed">
<Year>2010</Year>
<Month>1</Month>
<Day>22</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline">
<Year>2010</Year>
<Month>10</Month>
<Day>23</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList>
<ArticleId IdType="pubmed">20091020</ArticleId>
<ArticleId IdType="doi">10.1007/s00125-009-1618-y</ArticleId>
</ArticleIdList>
<ReferenceList>
<Reference>
<Citation>Diabetes. 2004 Dec;53(12):3033-40</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">15561931</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Autoimmun. 1997 Jun;10(3):245-50</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">9218750</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Diabetologia. 2005 Nov;48(11):2322-9</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">16211374</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Diabetologia. 1997 Jan;40(1):95-9</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">9028724</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Diabetologia. 2009 Sep;52(9):1881-8</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">19590848</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Diabetes. 1996 Jul;45(7):926-33</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">8666144</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Diabetes. 2004 Feb;53(2):384-92</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">14747289</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Diabetologia. 2008 Dec;51(12):2299-302</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">18850084</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Diabetes Care. 1997 Oct;20(10):1556-61</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">9314635</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Proc Natl Acad Sci U S A. 2007 Oct 23;104(43):17040-5</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">17942684</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>EMBO J. 1996 May 1;15(9):2102-14</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">8641276</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Clin Invest. 2001 Nov;108(9):1247-52</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">11696564</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Diabetologia. 2006 May;49(5):881-90</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">16514546</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>N Engl J Med. 2002 May 30;346(22):1692-8</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">12037148</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Diabetes. 2008 Oct;57(10):2693-7</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">18591387</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Diabetes. 2004 Sep;53(9):2330-7</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">15331542</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Diabetologia. 2002 Dec;45(12):1658-66</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">12488955</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Curr Diab Rep. 2002 Aug;2(4):347-53</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">12643195</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Diabetologia. 2008 Mar;51(3):488-92</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">18193190</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Diabetes. 1994 Oct;43(10):1254-9</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">7926297</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Clin Endocrinol Metab. 1996 Dec;81(12):4264-7</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">8954025</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Proc Natl Acad Sci U S A. 1994 Jan 4;91(1):123-7</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">8278351</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Diabetologia. 2005 Apr;48(4):687-94</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">15756536</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Diabetologia. 2010 Jan;53(1):36-44</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">19898832</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Clin Invest. 1998 Jan 15;101(2):327-36</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">9435304</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Diabetes. 2005 Dec;54 Suppl 2:S25-31</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">16306336</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Biol Chem. 1996 Jul 26;271(30):18161-70</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">8663434</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Best Pract Res Clin Endocrinol Metab. 2001 Sep;15(3):371-89</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">11554777</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>N Engl J Med. 2005 Jun 23;352(25):2598-608</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">15972866</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Clin Endocrinol Metab. 1995 Mar;80(3):846-51</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">7883841</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Immunol. 1996 Sep 15;157(6):2707-11</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">8805677</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Hum Immunol. 2002 Jan;63(1):40-50</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">11916169</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</PubmedArticle>